Fungal meningitis screening: Difference between revisions
Jump to navigation
Jump to search
Prince Djan (talk | contribs) No edit summary |
m Bot: Removing from Primary care |
||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{PTD}} | {{CMG}}; {{AE}} {{PTD}} | ||
==Overview== | ==Overview== | ||
It is recommended that patients with [[CD4]] counts ≤ 100 cells/μl, should have routine [[Cryptococcosis|cryptococcal]] antigen screening. Patients with positive result are offered preemptive [[Antifungal drug|anti-fungal therapy]].<ref name="pmid28166254">{{cite journal| author=Cassim N, Schnippel K, Coetzee LM, Glencross DK| title=Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa. | journal=PLoS One | year= 2017 | volume= 12 | issue= 2 | pages= e0171675 | pmid=28166254 | doi=10.1371/journal.pone.0171675 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28166254 }} </ref><ref name="pmid28134711">{{cite journal| author=Greene G, Sriruttan C, Le T, Chiller T, Govender NP| title=Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease. | journal=Curr Opin HIV AIDS | year= 2017 | volume= 12 | issue= 2 | pages= 139-147 | pmid=28134711 | doi=10.1097/COH.0000000000000347 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28134711 }} </ref> | |||
==Screening== | ==Screening== | ||
Screening is recommended in some types of fungal meningitis. | |||
[[Cryptococcosis|Cryptococcal]] meningitis commonly affects patients with [[CD4]] count are ≤ 100 cells/μl. It is responsible for major cause of [[mortality]] and [[morbidity]] in [[Human Immunodeficiency Virus (HIV)|HIV]] individuals. It is recommended that patients with [[CD4]] counts ≤ 100 cells/μl, should have routine [[Cryptococcosis|cryptococcal]] antigen screening. Patients with positive result are offered preemptive [[Antifungal drug|anti-fungal therapy]].<ref name="pmid28166254">{{cite journal| author=Cassim N, Schnippel K, Coetzee LM, Glencross DK| title=Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa. | journal=PLoS One | year= 2017 | volume= 12 | issue= 2 | pages= e0171675 | pmid=28166254 | doi=10.1371/journal.pone.0171675 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28166254 }} </ref><ref name="pmid28134711">{{cite journal| author=Greene G, Sriruttan C, Le T, Chiller T, Govender NP| title=Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease. | journal=Curr Opin HIV AIDS | year= 2017 | volume= 12 | issue= 2 | pages= 139-147 | pmid=28134711 | doi=10.1097/COH.0000000000000347 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28134711 }} </ref> | |||
==References== | ==References== | ||
| Line 10: | Line 13: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Emergency mdicine]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | |||
[[Category:Neurology]] | |||
Latest revision as of 21:48, 29 July 2020
|
Fungal meningitis Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Fungal meningitis screening On the Web |
|
American Roentgen Ray Society Images of Fungal meningitis screening |
|
Risk calculators and risk factors for Fungal meningitis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Prince Tano Djan, BSc, MBChB [2]
Overview
It is recommended that patients with CD4 counts ≤ 100 cells/μl, should have routine cryptococcal antigen screening. Patients with positive result are offered preemptive anti-fungal therapy.[1][2]
Screening
Screening is recommended in some types of fungal meningitis. Cryptococcal meningitis commonly affects patients with CD4 count are ≤ 100 cells/μl. It is responsible for major cause of mortality and morbidity in HIV individuals. It is recommended that patients with CD4 counts ≤ 100 cells/μl, should have routine cryptococcal antigen screening. Patients with positive result are offered preemptive anti-fungal therapy.[1][2]
References
- ↑ 1.0 1.1 Cassim N, Schnippel K, Coetzee LM, Glencross DK (2017). "Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa". PLoS One. 12 (2): e0171675. doi:10.1371/journal.pone.0171675. PMID 28166254.
- ↑ 2.0 2.1 Greene G, Sriruttan C, Le T, Chiller T, Govender NP (2017). "Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease". Curr Opin HIV AIDS. 12 (2): 139–147. doi:10.1097/COH.0000000000000347. PMID 28134711.